Intrexon (XON) Posts Q1 Net Income of 26c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intrexon Announces First Quarter 2015 Financial Results
May 11, 2015 4:05 PM EDTGERMANTOWN, Md., May 11, 2015 /PRNewswire/ --Â Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its first quarter results for 2015.Â
Business Highlights and Recent Developments:
Entered into an exclusive collaboration and license agreement with the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, to develop and commercialize chimeric antigen receptor T-cell (CAR-T) cancer therapies. Utilizing Intrexon's cell engineering techniques and RheoSwitch® platform, the collaboration aims to develop leading-edge products that... More